4D Molecular Therapeutics To Present Interim Data From Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial For Cystic Fibrosis At 47 European Cystic Fibrosis Conference

Author: Benzinga Newsdesk | May 30, 2024 08:07am

Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m. BST
Company to host webcast on Thursday, June 6, 2024 at 8:00 a.m. ET

EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))))), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 47th European Cystic Fibrosis Conference, taking place in Glasgow, UK. The Company will host a webcast to discuss the data in detail and provide a program update on Thursday, June 6 at 8:00 a.m. ET.

Posted In: FDMT